Abstract
Introduction

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening conditions characterized by high mor-
tality, rapid onset of respiratory failure following extensive inflammation, lung oedema and alveolar haemorrhage [1] . In ALI and ARDS, inflammatory cells migrate into the lung parenchyma and release mediators that destroy bacteria but also cause tissue disruption and lung injury [2] . Although [3] . In addition, recent work has also demonstrated the derivation of pulmonary progenitor cells such as type II pneumocytes from embryonic stem cells (hESCs) [4] , as well as integrin-dependent differentiation and adhesion of stem cells in lung tissue [5] .
Hypoxia-induced mitogenic factor (HIMF), an autocrine and paracrine cytokine primarily expressed in airway and alveolar epithelial cells, plays a number of roles in lung disease, including lung cell proliferation and development, in addition to mitogenic, angiogenic and vasoconstrictive effects [6] [7] [8] . Furthermore, HIMF has anti-apoptotic functions that can protect against the development of lipopolysaccharide (LPS)-induced ALI through the reservation of surfactant protein C production [9] [10] .
In [11] . 
Lentiviral transduction and identification of MSCs
Experimental design
The experimental design is outlined in Figure 1 . (Fig. 3) .
Results
MSC isolation, identification and transduction
MSC transplant improved LPS-induced lung injury independent of HIMF
The severity of LPS-induced lung injury was evaluated using a semiquantitative histopathology scoring system. Lung injury occurred after LPS challenge, with the peak of injury observed on 3 and 7 days after treatment with PBS (Fig. 4A) . (Fig. 5) . Increased interalveolar septal thickening and fibroblast proliferation were observed 14 days after transplantation of MSCs-HIMF (Fig. 5) . Intra-alveolar septal thickness increased 4-fold 3 days after LPS exposure (Fig. 4C) (Fig. 4D, P Fig. 6A 0.05, Fig. 6F ). Fig. 7A  and B) . Lung levels of TNF-␣ protein were consistent with the changes observed in TNF-␣ mRNA expression (Fig. 7C and D) . Levels of IL-10 mRNA (Fig. 7E and F) and protein (Fig. 7G and H 
. Transplantation of MSCs or MSCs-null vector prevented LPS-induced increases in intraalveolar septal thickness on day 7 compared to treatment with PBS (P Ͻ 0.05, Fig. 4C and D). No such effect was observed after treatment with MSCs-HIMF. In fact, intra-alveolar septal thickness increased by 74% 14 days after transplantation of MSCs-HIMF, significantly higher than that observed in PBS-treated animals
and C). Treatment with MSCs alone or MSCs-null vector consistently inhibited LPS-induced lung oedema after 7 days. This did not occur after treatment with MSCs-HIMF. Animals treated with MSCs-HIMF showed significantly increased MPO values 7 and 14 days after LPS treatment compared to animals treated with PBS, MSCs alone or MSCs-null vector (P Ͻ 0.05, Fig. 6C and D). The total protein concentration in BAL fluid was significantly higher 3 days after LPS challenge (P Ͻ 0.05 versus day 0, Fig. 6E). However, these levels were reduced significantly after treatment with MSCs alone or MSCs-null vector when compared to PBS treatment. Treatment with MSCs-HIMF resulted in a significant increase in total BAL protein concentration 14 days after LPS challenge when compared to other treatments (P Ͻ
MSCs treatment increased IL-10 and decreased TNF-␣ expression levels
Levels of TNF-␣ mRNA expression were significantly higher in lung tissue 3 days after LPS challenge in animals treated with PBS when compared to day 0 (P Ͻ 0.05, Fig. 7A). Levels of TNF-␣ mRNA in the lungs of animals treated with MSCs or MSCs-null vector were significantly lower than those treated with PBS on days 3 and 7 after LPS administration, but remained higher than observed on day 0 (P Ͻ 0.05). There was a significant increase
MSCs decreased lung fibrosis
We observed an increased number of myofibroblasts in the MSCs-HIMF-treated group via staining with ␣-SMA antibodies. Animals treated with MSCs alone or MSCs-null vector showed less
Fig. 3 Transduction of MSCs with HIMF-eGFP or eGFP and identification five days after transduction. Fluorescence (left) and phase contrast microscopy (right) showing the expression of eGFP in MSCs-HIMF (A and B) and MSCsnull vector (C and D) five days after lentiviral transduction at a MOI ϭ 5 ϫ 200. MSCs without eGFP transduction (E and F) are shown as a negative control for autofluorescence. RT-PCR (G) and Western blot (H) indicating HIMF expression in MSCs-HIMF.
collagen deposition and fewer ␣-SMA ϩ cells after LPS treatment (Fig. 8A-D) . [19] . In the present study, BM-derived MSCs were cultured as described previously [20] . We found that systemic transplantation of MSCs could reduce LPS-induced lung injury, leucocyte recruitment, over-production of inflammatory 
Levels of hydroxyproline in the lungs of animals treated with MSCs alone or MSCs-null vector were significantly lower than those treated with PBS 14 days after LPS challenge (Fig. 8E and F, P Ͻ 0.05).
Discussion
ALI is characterized by extensive damage to the barrier of the lung epithelium and endothelium, neutrophil influx into the lung and an imbalance between pro-inflammatory and anti-inflammatory
Fig. 4 The histopathology score of lung injury was evaluated after LPS challenge (A, B). Transplantation of MSCs prevented LPS-induced increase in lung
Fig. 5 Histopathology of injured lungs on day 7 (A-H) and day 14 (a-f). Lung tissue sections were stained with haematoxylin and eosin. Histopathological changes in the lungs are shown at low (ϫ100) and high (ϫ400) magnification. (A, a) MSCs-HIMF transplantation; (C, c) MSC transplantation; (E, e) controls; (G) MSC-null vector transplantation. mediators. LPS, a glycolipid of the outermost membrane of gramnegative bacteria, was used in this study to induce ALI and sub-ALI, as measured by hyper-production of the pro-inflammatory factor TNF-␣, neutrophil infiltrates, alveolar congestion
